files/journal/2022-09-03_18-51-40-000000_599.png

Research Journal of Medical Sciences

ISSN: Online 1993-6095
ISSN: Print 1815-9346
About US
Editors
Issues
Pages
Indexed in
173
Views
21
Downloads

Evaluation of ER, PR, HER 2 NEU in Carcinoma Breast at Tertiary Care Centre in Kanyakumari District

Sreeja K. Bhasy, Evelyn Angel, Anisha Saheen, Veer Dinesh, Ashwathy Senan, Monica Tefilah and Roselin Samuel
Page: 389-393 | Received 20 Feb 2024, Published online: 16 Mar 2024

Download Citation
https://doi.org/10.36478/10.36478/makrjms.2024.2.389.393

Full Text Reference XML File PDF File

Abstract

Breast cancer is a heterogeneous disease with various subtypes defined by the expression of hormone receptors such as Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2/neu. The expression of these receptors plays a crucial role in determining the prognosis and guiding the treatment strategies. This study aims to evaluate the prevalence of ER, PR and HER2/neu expression in breast carcinoma patients at a tertiary care center in Kanyakumari District. A retrospective study was conducted using medical records of breast carcinoma patients treated at the tertiary care center from January 2018 to December 2022. Data were collected on demographics, tumor characteristics and receptor status (ER, PR, HER2/neu). Statistical analyses were performed to determine the prevalence and co‐expression patterns of these receptors. The study included 100 patients diagnosed with breast carcinoma. The prevalence of ER, PR and HER2/neu expression was found to be 65%, 55% and 25%, respectively. Triple‐negative breast cancer (TNBC) was observed in 15% of the cases. Significant associations were identified between receptor status and tumor characteristics, such as tumor size, histological grade lymph node involvement. The findings highlight the importance of receptor status evaluation in guiding treatment decisions. This study underscores the significant variability in receptor expression among breast carcinoma patients. Routine evaluation of ER, PR and HER2/neu is essential for personalized treatment planning and improving patient outcomes. Further research is needed to explore the clinical implications of these findings in the regional context.

How to cite this article:

Sreeja K. Bhasy, Evelyn Angel, Anisha Saheen, Veer Dinesh, Ashwathy Senan, Monica Tefilah and Roselin Samuel. Evaluation of ER, PR, HER 2 NEU in Carcinoma Breast at Tertiary Care Centre in Kanyakumari District.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.2.389.393
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.2.389.393